Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Treatment of vaginal candidiasis,Oropharyngeal and esophageal candidiasis,Candidal urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia,Prophylaxis in bone marrow transplant recipients with chemotherapy or radiation therapy,Cryptococcal meningitis and cryptococcosis at other sites
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
400 mg IV on day 1, then 200 mg IV once daily
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is approximately 30 hours (range 20–50 hours) in adults; prolonged in renal impairment. In neonates, half-life is longer (up to 90 hours).
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Fluconazole is primarily metabolized by the liver, with approximately 11% of the dose metabolized; the unchanged drug is the major circulating entity. Hepatic metabolism involves N-oxidation and glucuronidation, but specific CYP enzymes are not significantly involved. It is a moderate inhibitor of CYP2C9 and CYP3A4.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal; approximately 80% of the dose is excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Approximately 11–12% bound to plasma proteins (mainly albumin).
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Approximately 0.7 L/kg, indicating extensive distribution into total body water; penetrates well into tissues and CSF.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Oral bioavailability is >90% (virtually complete). IV administration is 100%.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
For Cr Cl 50-90 m L/min: no adjustment; Cr Cl 10-49 m L/min: 50% dose or interval doubling; Cr Cl <10 m L/min (not on dialysis): 50% dose or interval doubling; on hemodialysis: one full dose after each dialysis session
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment for Child-Pugh A or B; caution in severe hepatic impairment (Child-Pugh C) with monitoring
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Loading dose: 12 mg/kg IV (max 400 mg) on day 1, then 6 mg/kg IV (max 200 mg) once daily; for weight <40 kg, adjust based on weight using these mg/kg doses
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Dose based on renal function; no specific age-related adjustment beyond renal considerations
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA black box warning.
None.
Hepatic toxicity: severe liver injury including fatal cases; discontinue if signs of liver disease develop,Anaphylaxis and allergic reactions,QT prolongation and torsade de pointes; use with caution in patients with proarrhythmic conditions,Adrenal insufficiency: fluconazole may inhibit adrenal steroidogenesis,Fetal harm: use during pregnancy only if benefit outweighs risk; multiple congenital anomalies reported,Skin reactions: monitoring for exfoliative disorders
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to fluconazole, azole antifungals, or any component of the formulation,Concomitant use with drugs that are CYP3A4 substrates with QT prolongation potential (e.g., cisapride, pimozide, quinidine, erythromycin, certain statins) due to risk of serious cardiac arrhythmias,Caution in patients with hepatic impairment, pregnancy, and breastfeeding
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No significant food interactions with IV formulation. Oral fluconazole absorption is not affected by food. Avoid grapefruit juice? Not specifically contraindicated, but grapefruit juice may rarely affect CYP3A4 metabolism; no documented interaction with fluconazole.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
First trimester: Multiple case reports and epidemiological studies suggest an increased risk of spontaneous abortion and congenital anomalies, particularly craniofacial and skeletal malformations, with high-dose (400-800 mg/day) fluconazole exposure. Low-dose (150 mg single dose) exposure is not consistently associated with increased risk. Second and third trimesters: Standard doses are not associated with teratogenic risk, but prolonged high-dose therapy may increase risk of preterm birth and low birth weight.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Fluconazole is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 0.9-1.0. Concentrations in milk are similar to maternal plasma. After a single 150 mg dose, the infant dose is estimated at 2-3 mg/kg/day, which is less than the neonatal therapeutic dose. The American Academy of Pediatrics considers fluconazole compatible with breastfeeding, but caution is advised with prolonged high-dose therapy.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Pregnancy does not significantly alter fluconazole pharmacokinetics; however, increased volume of distribution and enhanced clearance may occur, potentially requiring higher doses for severe infections. For systemic mycoses, standard dosing is generally used. For vaginal candidiasis, a single 150 mg oral dose is effective. For cryptococcal meningitis in pregnancy, recommended maintenance dose is 200-400 mg daily after loading dose (400 mg). Monitor therapeutic response and adjust dose based on clinical efficacy and local resistance patterns.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
DIFLUCAN (fluconazole) in 0.9% sodium chloride is an IV formulation for patients unable to take oral. Monitor renal function and adjust dose if Cr Cl <50 m L/min. Caution with hepatotoxic drugs; check LFTs. QTc prolongation risk: avoid with other QTc-prolonging agents and electrolyte abnormalities. Transition to oral fluconazole when feasible. Incompatible with amphotericin B and other drugs; use separate lines.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Do not mix with other medications in the same IV line.,Report any signs of liver problems (yellowing skin/eyes, dark urine, severe nausea) or irregular heartbeat.,Complete the full course even if feeling better.,May cause dizziness; avoid driving if affected.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Fluconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, a key component of the fungal cell membrane. This disrupts membrane integrity and function.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 400 mg IV on day 1, then 200 mg IV once daily. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. First trimester: Multiple case reports and epidemiological studies suggest an increased risk of spontaneous abortion and congenital anomalies, particularly craniofacial and skeleta. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.